Sulfonylureas and insulin analogs, which are commonly used as second- and third-line therapies for diabetes, may lead to increased insulin-like growth factor levels and hence promote prostate cancer growth and simultaneously increase PSA levels. The gene discussed is INS; the disease is prostate cancer.